《新股表现》翰森制药(03692.HK)半日收17.96元高上市价26%
翰森制药(03692.HK)暗盘收16.02元,高上市价逾12%;该股首挂高开14%报16.3元,最多涨31%高见18.7元遇压,半日收17.96元,较上市价14.26元,高26%,半日成交9,659万股,涉资1.63亿元。
翰森是为数不多以研发为主导的中国制药公司之一,其於中枢神经系统疾病、抗肿瘤、抗感染及糖尿病方面拥有广泛、多元化及领先的药物组合,公司还专注於消化道及心血管治疗领域。是次来港上市共发5.51亿股,并已引入高瓴资本、博裕资本、GIC、汇桥资本、奥博资本、上海医药(02607.HK)及维梧资本等九名基石投资者,合共认购1.89亿股(禁售股半年);7%公开发售获近11倍超购,认购一手中签率60%,股份以招股范围(13.06-14.26元)上限定价,料集资净额76.4亿元,主要用於研发、扩充研发团队及在研发技术投资、用作生产体系、建设新生产线、升级现有生产设施并提高其自动化水平、以及销售和学术推广以配合新产品上市等。上市联席保荐人分别为大摩及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.